Crinetics Pharmaceuticals earnings were -$501.6M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest CRNX earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$120.9M, down 5.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, CRNX reported annual earnings of -$465.3M, with 55.9% growth.
Crinetics Pharmaceuticals Earnings Reports & History FAQ
What were Crinetics Pharmaceuticals's earnings last quarter?
On CRNX's earnings call on Aug 4, 2026, Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q2 2026 earnings per share (EPS) of -$1.14, up 7.32% year over year. Total CRNX earnings for the quarter were -$120.86 million. In the same quarter last year, Crinetics Pharmaceuticals's earnings per share (EPS) was -$1.23.
Is Crinetics Pharmaceuticals profitable or losing money?
As of the last Crinetics Pharmaceuticals earnings report, Crinetics Pharmaceuticals is currently losing money. Crinetics Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$501.61 million, a 35.63% increase year over year.
What was CRNX's earnings growth in the past year?
As of Crinetics Pharmaceuticals's earnings date in Aug 4, 2026, Crinetics Pharmaceuticals's earnings has grown year over year. CRNX earnings in the past year totalled -$501.61 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.